Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 13;20(12):2887.
doi: 10.3390/ijms20122887.

Telomerase and Telomeres Biology in Thyroid Cancer

Benedetta Donati  1 , Alessia Ciarrocchi  2
Affiliations
Review

Telomerase and Telomeres Biology in Thyroid Cancer

Benedetta Donati et al. Int J Mol Sci. .

Abstract

Telomere and telomerase regulation contributes to the onset and evolution of several tumors, including highly aggressive thyroid cancers (TCs). TCs are the most common endocrine malignancies and are generally characterized by a high rate of curability. However, a small but significant percentage develops distant metastasis or progresses into undifferentiated forms associated with bad prognosis and for which poor therapeutic options are available. Mutations in telomerase reverse transcriptase (TERT) promoter are among the most credited prognostic marker of aggressiveness in TCs. Indeed, their frequency progressively increases passing from indolent lesions to aggressive and anaplastic forms. TERT promoter mutations create binding sites for transcription factors, increasing TERT expression and telomerase activity. Furthermore, aggressiveness of TCs is associated with TERT locus amplification. These data encourage investigating telomerase regulating pathways as relevant drivers of TC development and progression to foster the identification of new therapeutics targets. Here, we summarize the current knowledge about telomere regulation and TCs, exploring both canonical and less conventional pathways. We discuss the possible role of telomere homeostasis in mediating response to cancer therapies and the possibility of using epigenetic drugs to re-evaluate the use of telomerase inhibitors. Combined treatments could be of support to currently used therapies still presenting weaknesses.

Keywords: BRD4; EMT; TERT promoter; combined therapies; epigenetic drugs; telomerase; telomeres; thyroid cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic model representing TERT promoter regulation in TCs and some hypotheses of therapeutic interventions. The figure shows the long-range chromatin interaction mediated by GABP factors and BRD4 on the mutated TERT promoter, and all the transcription factors positively influencing TERT expression and for whom we described a possible connection with TERT promoter in TCs. We also summarized the new proposed therapies for aggressive TCs, that may also rely on telomerase inhibition. In particular, MKI that acts on MAPK signaling and epigenetic drugs such as BETi and HDACi that may counteract TERT expression by impairing the function of TFs such as c-Myc and BRD4. Moreover, telomeres deregulation and the subsequent genomic instability, here represented by TERT promoter mutations, may influence the response to immunotherapeutic treatments. Overall, this model shows that there are many possible therapeutic combinations to counteract the aberrant activity of telomerase in TCs and consequently to inhibit one of the major trigger of TC aggressiveness.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blackburn E.H. Structure and function of telomeres. Nature. 1991;350:569–573. doi: 10.1038/350569a0. - DOI - PubMed
    1. Palm W., de Lange T. How shelterin protects mammalian telomeres. Ann. Rev. Genet. 2008;42:301–334. doi: 10.1146/annurev.genet.41.110306.130350. - DOI - PubMed
    1. Chen Y. The structural biology of the shelterin complex. Biol. Chem. 2019;400:457–466. doi: 10.1515/hsz-2018-0368. - DOI - PubMed
    1. Tomita K. How long does telomerase extend telomeres? Regulation of telomerase release and telomere length homeostasis. Curr. Genet. 2018;64:1177–1181. doi: 10.1007/s00294-018-0836-6. - DOI - PMC - PubMed
    1. de Lange T. Shelterin-Mediated Telomere Protection. Ann. Rev. Genet. 2018;52:223–247. doi: 10.1146/annurev-genet-032918-021921. - DOI - PubMed